Cardiovascular revascularization medicine : including molecular interventions · 2025
Percutaneous micro-axial flow pump use during non-emergent high-risk PCI: Systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Elbenawi Hossam, Doma Mohamed, Cangut Busra, Abdelgalil Mahmoud Shaaban, Khlidj Yehya, Thakurathi Priyesh, Hammad Amer, Mohammed Fathia, Almaadawy Omar, Farhoud Hassan, Ghaly Ramy, Khan Ubaid, Abdelkarim Islam, Zaaya Morad, Ibrahim Ramzi, Aqtash Obadah, Sadek Yasser Ahmed, Al-Azizi Karim M, Lin Chien-Jung, Goldsweig Andrew M, Elbadawi Ayman, Stone Gregg W, Elgendy Islam Y
Аннотация
BACKGROUND: Percutaneous micro-axial flow pumps (mAFP) are increasingly used for hemodynamic support during high-risk percutaneous coronary interventions (PCI) despite limited evidence supporting their effectiveness. We conducted a meta-analysis to assess the effectiveness and safety of mAFP use during non-emergent high-risk PCI procedures.
METHODS: Electronic databases were searched for studies comparing percutaneous mAFP versus control for non-emergent high-risk PCI. The primary outcome was the incidence of major adverse cardiac events (MACE).
RESULTS: Eight studies (one randomized, seven observational) with 4688 patients were included. There were no significant differences in the risk of MACE within 30 days (risk ratio [RR] 1.30, 95% confidence interval [CI] 0.81-2.10) or at 1 year (RR 1.08; 95 % CI 0.58-1.98) in patients treated with vs. without a mAFP during high-risk PCI. Nor was the risk of mortality different between groups. Peri-procedural complications, including acute kidney injury, major bleeding, blood transfusions, myocardial infarction, and stroke, were not increased with the mAFP. The subgroup of patients who received mAFP prior to PCI again had similar risk of MACE and mortality compared with the control. However, in this group, mAFP use was associated with higher in-hospital risks of major bleeding (RR 2.77; 95 % CI 1.28-5.98), blood transfusion (RR 2.20; 95 % CI 1.17-4.15) and in-hospital or 30-day myocardial infarction (RR 1.68; 95 % CI 1.03-2.73).
CONCLUSIONS: mAFP use was not associated with improved outcomes among patients undergoing non-emergent high-risk PCI. Given the potential for selection bias, ongoing large-scale randomized trials are necessary to determine its impact on efficacy and safety.
SOCIAL MEDIA ABSTRACT: In 4688 patients undergoing non-emergent high-risk PCI, use of a percutaneous micro-axial flow pump did not reduce MACE or mortality at 30 days or 6 months, and pre-PCI use was linked to higher risks of bleeding and in-hospital MI, warranting further large-scale trials.
METHODS: Electronic databases were searched for studies comparing percutaneous mAFP versus control for non-emergent high-risk PCI. The primary outcome was the incidence of major adverse cardiac events (MACE).
RESULTS: Eight studies (one randomized, seven observational) with 4688 patients were included. There were no significant differences in the risk of MACE within 30 days (risk ratio [RR] 1.30, 95% confidence interval [CI] 0.81-2.10) or at 1 year (RR 1.08; 95 % CI 0.58-1.98) in patients treated with vs. without a mAFP during high-risk PCI. Nor was the risk of mortality different between groups. Peri-procedural complications, including acute kidney injury, major bleeding, blood transfusions, myocardial infarction, and stroke, were not increased with the mAFP. The subgroup of patients who received mAFP prior to PCI again had similar risk of MACE and mortality compared with the control. However, in this group, mAFP use was associated with higher in-hospital risks of major bleeding (RR 2.77; 95 % CI 1.28-5.98), blood transfusion (RR 2.20; 95 % CI 1.17-4.15) and in-hospital or 30-day myocardial infarction (RR 1.68; 95 % CI 1.03-2.73).
CONCLUSIONS: mAFP use was not associated with improved outcomes among patients undergoing non-emergent high-risk PCI. Given the potential for selection bias, ongoing large-scale randomized trials are necessary to determine its impact on efficacy and safety.
SOCIAL MEDIA ABSTRACT: In 4688 patients undergoing non-emergent high-risk PCI, use of a percutaneous micro-axial flow pump did not reduce MACE or mortality at 30 days or 6 months, and pre-PCI use was linked to higher risks of bleeding and in-hospital MI, warranting further large-scale trials.